Iterum Historical Balance Sheet

ITRM Stock

USD 1.57 0.07 4.67%

Trend analysis of Iterum Therapeutics PLC balance sheet accounts such as Total Current Liabilities of 15 M or Net Tangible Assets of 14.9 M provides information on Iterum Therapeutics' total assets, liabilities, and equity, which is the actual value of Iterum Therapeutics PLC to its prevalent stockholders. By breaking down trends over time using Iterum Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Iterum Therapeutics PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iterum Therapeutics PLC is a good buy for the upcoming year.

Iterum Therapeutics Inventory

(2.24 Million)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Iterum Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Iterum Therapeutics PLC at a specified time, usually calculated after every quarter, six months, or one year. Iterum Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Iterum Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Iterum currently owns. An asset can also be divided into two categories, current and non-current.

Iterum Therapeutics Balance Sheet Chart

At this time, Iterum Therapeutics' Liabilities And Stockholders Equity is very stable compared to the past year. As of the 31st of January 2025, Non Current Liabilities Total is likely to grow to about 31.1 M, though Total Stockholder Equity is likely to grow to (5.5 M).

Total Assets Other Current Liab Total Current Liabilities Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Iterum Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Iterum Therapeutics PLC books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Iterum Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Iterum Therapeutics PLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Iterum Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Iterum Therapeutics PLC are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Iterum Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Iterum Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	6.3M	8.5M	9.8M	10.5M
Total Assets	66.8M	26.3M	30.2M	57.0M

Other Current Liab Total Assets

Iterum Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Preferred Stock Total Equity	Total Current Assets	Common Stock	Other Liab
Total Assets		0.14	-0.1	0.57	0.55	0.06	-0.36	-0.09	0.42	0.33	0.22	0.19	0.97	0.53	0.37	0.54	0.9	0.4	0.47	0.26	0.41	0.27	0.49	0.96	0.58	0.43
Other Current Liab	0.14		0.52	-0.57	-0.56	0.65	-0.47	-0.15	-0.22	0.51	0.5	0.77	-0.01	0.39	0.61	0.25	0.12	0.65	0.57	0.39	0.38	0.83	0.48	-0.02	0.37	0.26
Total Current Liabilities	-0.1	0.52		-0.72	-0.68	0.58	-0.38	0.72	-0.52	0.76	0.79	0.74	-0.34	0.56	0.36	0.03	-0.12	0.74	0.55	0.73	0.27	0.76	0.54	-0.35	0.09	0.11
Total Stockholder Equity	0.57	-0.57	-0.72		0.92	-0.68	0.36	-0.35	0.73	-0.29	-0.36	-0.44	0.71	-0.06	-0.4	0.15	0.47	-0.48	-0.31	-0.19	-0.21	-0.61	-0.2	0.73	0.12	-0.14
Net Tangible Assets	0.55	-0.56	-0.68	0.92		-0.49	0.13	-0.3	0.53	-0.45	-0.52	-0.59	0.71	-0.21	-0.18	0.12	0.55	-0.47	-0.14	-0.27	0.03	-0.57	-0.05	0.73	0.08	0.14
Net Debt	0.06	0.65	0.58	-0.68	-0.49		-0.88	0.3	-0.77	0.31	0.28	0.37	-0.06	0.31	0.89	0.27	0.31	0.74	0.81	0.19	0.79	0.83	0.75	-0.06	0.29	0.73
Retained Earnings	-0.36	-0.47	-0.38	0.36	0.13	-0.88		-0.27	0.51	-0.25	-0.18	-0.2	-0.28	-0.34	-0.97	-0.44	-0.58	-0.74	-0.91	-0.07	-0.96	-0.75	-0.8	-0.28	-0.44	-0.93
Accounts Payable	-0.09	-0.15	0.72	-0.35	-0.3	0.3	-0.27		-0.47	0.53	0.56	0.24	-0.25	0.42	0.09	-0.1	-0.05	0.48	0.38	0.56	0.23	0.34	0.43	-0.26	-0.12	0.11
Cash	0.42	-0.22	-0.52	0.73	0.53	-0.77	0.51	-0.47		0.01	-0.02	-0.04	0.5	0.02	-0.46	0.07	0.09	-0.31	-0.36	-0.04	-0.4	-0.4	-0.43	0.48	0.1	-0.41
Non Current Assets Total	0.33	0.51	0.76	-0.29	-0.45	0.31	-0.25	0.53	0.01		0.99	0.9	0.1	0.89	0.23	0.29	0.17	0.81	0.54	0.83	0.2	0.74	0.52	0.07	0.38	-0.03
Non Currrent Assets Other	0.22	0.5	0.79	-0.36	-0.52	0.28	-0.18	0.56	-0.02	0.99		0.9	-0.02	0.83	0.16	0.19	0.04	0.77	0.47	0.85	0.12	0.71	0.46	-0.04	0.28	-0.12
Other Assets	0.19	0.77	0.74	-0.44	-0.59	0.37	-0.2	0.24	-0.04	0.9	0.9		-0.03	0.79	0.26	0.32	0.04	0.73	0.46	0.74	0.13	0.78	0.44	-0.05	0.44	-0.09
Cash And Short Term Investments	0.97	-0.01	-0.34	0.71	0.71	-0.06	-0.28	-0.25	0.5	0.1	-0.02	-0.03		0.34	0.3	0.51	0.89	0.19	0.35	0.05	0.37	0.07	0.36	1.0	0.52	0.43
Net Receivables	0.53	0.39	0.56	-0.06	-0.21	0.31	-0.34	0.42	0.02	0.89	0.83	0.79	0.34		0.3	0.66	0.45	0.75	0.57	0.63	0.33	0.66	0.58	0.32	0.71	0.13
Common Stock Total Equity	0.37	0.61	0.36	-0.4	-0.18	0.89	-0.97	0.09	-0.46	0.23	0.16	0.26	0.3	0.3		0.45	0.56	0.73	0.88	0.04	0.92	0.78	0.74	0.29	0.47	0.91
Common Stock Shares Outstanding	0.54	0.25	0.03	0.15	0.12	0.27	-0.44	-0.1	0.07	0.29	0.19	0.32	0.51	0.66	0.45		0.59	0.4	0.43	-0.1	0.47	0.37	0.35	0.5	0.99	0.44
Short Term Investments	0.9	0.12	-0.12	0.47	0.55	0.31	-0.58	-0.05	0.09	0.17	0.04	0.04	0.89	0.45	0.56	0.59		0.39	0.62	0.12	0.66	0.3	0.68	0.9	0.59	0.66
Non Current Liabilities Total	0.4	0.65	0.74	-0.48	-0.47	0.74	-0.74	0.48	-0.31	0.81	0.77	0.73	0.19	0.75	0.73	0.4	0.39		0.85	0.57	0.65	0.96	0.75	0.16	0.46	0.51
Capital Surpluse	0.47	0.57	0.55	-0.31	-0.14	0.81	-0.91	0.38	-0.36	0.54	0.47	0.46	0.35	0.57	0.88	0.43	0.62	0.85		0.4	0.92	0.85	0.93	0.33	0.47	0.77
Other Current Assets	0.26	0.39	0.73	-0.19	-0.27	0.19	-0.07	0.56	-0.04	0.83	0.85	0.74	0.05	0.63	0.04	-0.1	0.12	0.57	0.4		0.04	0.53	0.54	0.05	-0.01	-0.18
Other Stockholder Equity	0.41	0.38	0.27	-0.21	0.03	0.79	-0.96	0.23	-0.4	0.2	0.12	0.13	0.37	0.33	0.92	0.47	0.66	0.65	0.92	0.04		0.65	0.83	0.37	0.46	0.92
Total Liab	0.27	0.83	0.76	-0.61	-0.57	0.83	-0.75	0.34	-0.4	0.74	0.71	0.78	0.07	0.66	0.78	0.37	0.3	0.96	0.85	0.53	0.65		0.75	0.05	0.45	0.5
Preferred Stock Total Equity	0.49	0.48	0.54	-0.2	-0.05	0.75	-0.8	0.43	-0.43	0.52	0.46	0.44	0.36	0.58	0.74	0.35	0.68	0.75	0.93	0.54	0.83	0.75		0.36	0.39	0.66
Total Current Assets	0.96	-0.02	-0.35	0.73	0.73	-0.06	-0.28	-0.26	0.48	0.07	-0.04	-0.05	1.0	0.32	0.29	0.5	0.9	0.16	0.33	0.05	0.37	0.05	0.36		0.51	0.42
Common Stock	0.58	0.37	0.09	0.12	0.08	0.29	-0.44	-0.12	0.1	0.38	0.28	0.44	0.52	0.71	0.47	0.99	0.59	0.46	0.47	-0.01	0.46	0.45	0.39	0.51		0.41
Other Liab	0.43	0.26	0.11	-0.14	0.14	0.73	-0.93	0.11	-0.41	-0.03	-0.12	-0.09	0.43	0.13	0.91	0.44	0.66	0.51	0.77	-0.18	0.92	0.5	0.66	0.42	0.41

Click cells to compare fundamentals

Iterum Therapeutics Account Relationship Matchups

Iterum Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	32.8M	91.5M	66.8M	26.3M	30.2M	57.0M
Other Current Liab	34.3M	10.2M	6.3M	8.5M	9.8M	10.5M
Total Current Liabilities	28.9M	6.1M	196K	13.5M	15.5M	15.0M
Total Stockholder Equity	(50.6M)	50.2M	28.0M	(6.4M)	(5.8M)	(5.5M)
Net Tangible Assets	(26.2M)	(50.6M)	46.8M	26.3M	23.7M	14.9M
Net Debt	21.3M	(2.5M)	7.4M	12.9M	14.8M	15.6M
Retained Earnings	(286.9M)	(378.5M)	(422.9M)	(461.3M)	(415.2M)	(394.4M)
Accounts Payable	816K	878K	2.8M	5.0M	4.5M	3.4M
Cash	14.5M	27.4M	21.1M	6.1M	5.5M	5.2M
Non Current Assets Total	18.3M	10.2M	6.0M	663K	762.5K	724.3K
Non Currrent Assets Other	17.6M	6.6M	4.2M	63K	56.7K	53.9K
Other Assets	6.3M	10.9M	4.7M	831K	955.7K	907.9K
Cash And Short Term Investments	14.5M	81.3M	60.8M	23.9M	27.5M	45.9M
Net Receivables	865K	1.2M	513K	233K	268.0K	254.6K
Common Stock Shares Outstanding	24.0M	163.4M	12.2M	13.0M	14.9M	14.2M
Short Term Investments	2.4M	53.9M	39.7M	17.9M	20.5M	25.4M
Liabilities And Stockholders Equity	32.8M	91.5M	66.8M	26.3M	30.2M	57.0M
Non Current Liabilities Total	54.5M	35.2M	38.6M	19.1M	22.0M	31.1M
Other Current Assets	6.0M	717K	1.1M	1.4M	1.3M	1.2M
Other Stockholder Equity	235.9M	426.9M	451.2M	454.8M	523.0M	291.9M
Total Liab	83.4M	41.3M	38.8M	32.7M	37.6M	39.3M
Total Current Assets	14.5M	81.3M	60.8M	25.6M	29.4M	47.0M
Common Stock	494K	1.8M	126K	135K	155.3K	147.5K
Property Plant And Equipment Net	421K	91K	69K	600K	540K	365.7K
Net Invested Capital	(8.2M)	24.9M	56.5M	12.6M	11.3M	10.7M
Property Plant And Equipment Gross	421K	377K	353K	366K	329.4K	312.9K
Accumulated Other Comprehensive Income	(201K)	(353K)	(350K)	1K	900.0	945.0
Non Current Liabilities Other	19.2M	10.3M	1.3M	188K	216.2K	205.4K
Net Working Capital	(20.2M)	75.3M	53.4M	12.1M	10.9M	10.3M
Property Plant Equipment	7.7M	421K	91K	1.8M	1.7M	1.5M
Short Long Term Debt Total	35.9M	24.9M	28.5M	19.0M	21.8M	24.9M
Current Deferred Revenue	12.7M	(7.3M)	(2.5M)	(332K)	(298.8K)	(283.9K)
Long Term Debt	22.5M	24.9M	28.5M	19.0M	21.8M	21.2M
Inventory	(8.0M)	(3.7M)	(3.1M)	(1.9M)	(2.1M)	(2.2M)
Capital Stock	494K	1.8M	126K	135K	155.3K	147.5K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports:

How To Invest In Iterum

Details

Is Iterum Stock a good investment?

Details

What is Iterum Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.76)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.73)

Return On Equity

(5.56)

The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iterum Historical Balance Sheet

Iterum Therapeutics Inventory

(2.24 Million)

About Iterum Balance Sheet Analysis

Iterum Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Iterum Therapeutics balance sheet Correlations

Iterum Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iterum Therapeutics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Common Stock	+ 0.99	Common Stock Shares Outstanding
Cash And Short Term Investments	+ 0.97	Total Assets
Total Current Assets	+ 0.96	Total Assets
Total Liab	+ 0.96	Non Current Liabilities Total

Common Stock Total Equity	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Other Liab	- 0.93	Retained Earnings
Capital Surpluse	- 0.91	Retained Earnings
Retained Earnings	- 0.88	Net Debt
Preferred Stock Total Equity	- 0.8	Retained Earnings